

InferTest™ by InferVision

World Leader in AI-powered medical imaging

Our goals

Research and develop products based on key technologies - AI and big data mining

Improve the efficiency of medical diagnosis and quality of patient service

Utilize the power of science and technology for improved patient care

Create seamless workflows

Founded in 2015, InferVision is a technology company using artificial intelligence to improve medical imaging quality and diagnosis. In the past four years, InferVision has been committed to developing products to analyze DR, CT, and MRI images through deep learning. As of February 2019, InferVision has partnered with more than 300 top hospitals and medical institutions worldwide, helping physicians with over 40,000 diagnoses every day and has established offices in China, Japan, the United States, and Germany.

*Statistics by June 2019



Contact us


www.infervision.com/en
contact@infervision.com

*Internal Use Only

Better Diagnosis | Greater Efficiency | Enhanced Outcomes

InferTest Process

- 1.Providers send sample data to be tested through highly secured connections
 - 2.InferTest processes the sample data
 - 3.Detailed analysis feedback returned within a week
- *There is no charge for this service



Product Introduction

InferTest is an AI-based tool for diagnosis of lung diseases from chest CT and nodule, bone fractures, and pneumothorax diagnosis from chest DR. InferTest improves disease detection rate by over 30%* by accurately and efficiently detecting false negative diagnosis.

*According to the statistics in "outcome comparison" section

*Internal Use Only

Disease type

Supported Disease Diagnosis:

- CT pulmonary nodule
- CT fracture
- DR pulmonary nodule
- DR bone fracture
- DR effusion
- DR pneumothorax

Supported CT Layer Thickness:

0.625mm, 1mm, 1.25mm, 1.5mm, 2mm

Outcome Comparison


CT Lung Screening

Without AI: >5mm nodule recognition is 65.72%
 With AI: >5mm nodule recognition rate is 93.14%

Chest Film

Without AI: nodule recognition rate is 50.3%
 With AI: nodule recognition is 86.1%

Inferision AI significantly improves the detection rate of pulmonary nodules



>6mm,>5GGN,mass false negative